TEVA - Teva- Pharmaceutical Industries Ltd. - ADR
Close
18.87
0.140 0.742%
Share volume: 10,069,878
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$18.73
0.14
0.75%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-10 | 2023-05-10 | 2023-08-02 | 2023-11-09 | 2024-02-12 | 2024-05-08 | 2024-07-31 | |
| Assets | |||||||||
| Total Assets | 44.254 B | 44.006 B | 43.457 B | 43.094 B | 42.087 B | 43.478 B | 42.772 B | 41.339 B | |
| Current Assets | 11.454 B | 12.051 B | 11.501 B | 12.087 B | 11.424 B | 12.485 B | 12.297 B | 11.633 B | |
| Inventories | 3.859 B | 3.833 B | 4.118 B | 4.109 B | 4.051 B | 4.022 B | 3.949 B | 3.927 B | |
| Other Current Assets | 1.624 B | 1.711 B | 1.795 B | 1.714 B | 1.688 B | 1.759 B | 1.831 B | 1.613 B | |
| Short Term Investments | 1.624 B | 1.711 B | 1.795 B | 1.714 B | 1.688 B | 1.759 B | 1.831 B | 1.613 B | |
| Total Receivables | 3.730 B | 3.696 B | 3.435 B | 3.539 B | 3.385 B | 3.408 B | 3.456 B | 3.766 B | |
| Current Cash | 2.225 B | 2.801 B | 2.143 B | 2.669 B | 2.249 B | 3.226 B | 2.991 B | 2.258 B | |
| Total Non-current Assets | 32.800 B | 31.955 B | 31.956 B | 31.007 B | 30.663 B | 30.993 B | 30.475 B | 29.706 B | |
| Property Plant Equipment | 5.568 B | 5.739 B | 5.751 B | 5.712 B | 5.622 B | 5.750 B | 5.618 B | 5.573 B | |
| Other Assets | 438.000 M | 441.000 M | 450.000 M | 443.000 M | 477.000 M | 470.000 M | 470.000 M | 434.000 M | |
| Intangible Assets | 6.393 B | 6.270 B | 5.964 B | 5.738 B | 5.525 B | 5.387 B | 5.056 B | 4.853 B | |
| Goodwill | 18.433 B | 17.633 B | 17.799 B | 17.118 B | 16.885 B | 17.177 B | 17.007 B | 16.488 B | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 44.254 B | 44.006 B | 43.457 B | 43.094 B | 42.087 B | 43.478 B | 42.772 B | 41.339 B | |
| Total liabilities | 35.485 B | 36.109 B | 35.595 B | 36.042 B | 35.155 B | 35.973 B | 35.495 B | 34.980 B | |
| Total current liabilities | 11.534 B | 11.468 B | 10.412 B | 11.843 B | 11.392 B | 12.247 B | 13.792 B | 13.039 B | |
| Accounts Payable | 1.635 B | 1.887 B | 2.381 B | 2.508 B | 2.280 B | 2.602 B | 2.439 B | 2.366 B | |
| Other liabilities | 3.846 B | 3.847 B | 3.869 B | 3.973 B | 3.818 B | 4.019 B | 3.991 B | 4.356 B | |
| Current long term debt | 2.769 B | 2.109 B | 1.023 B | 1.980 B | 1.479 B | 1.672 B | 3.060 B | 2.094 B | |
| Long term debt | 18.497 B | 19.103 B | 19.668 B | 18.698 B | 18.495 B | 18.161 B | 16.584 B | 16.547 B | |
| Other liabilities | 3.846 B | 3.847 B | 3.869 B | 3.973 B | 3.818 B | 4.019 B | 3.991 B | 4.356 B | |
| Minority interest | 751.000 M | 794.000 M | 751.000 M | 656.000 M | 582.000 M | 620.000 M | 265.000 M | 204.000 M | |
| Total Shareholder equity | 8.768 B | 7.897 B | 7.861 B | 7.050 B | 6.929 B | 7.505 B | 7.278 B | 6.359 B | |
| Common stock | 1.111 B | 1.112 B | 1.115 B | 1.120 B | 1.121 B | 1.120 B | 1.123 B | 1.133 B | |
| Retained earnings | -11.660 B | -12.882 B | -13.086 B | -13.950 B | -13.870 B | -13.534 B | -13.673 B | -14.519 B |